The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Cervix Uteri

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Cervix Uteri


Psychiatry related information on Cervix Uteri

  • Mating itself did not increase circulating oxytocin or cortisol; uterine motility remained unchanged during and after copulation but the cervix was significantly stimulated during teasing and after copulation [6].
  • VIP inhibits the spontaneous motor activity (including tone) in isolated preparations of uterine cervix from oophorectomized rats, but has no direct effect on preparations from estrogen-treated animals [7].

High impact information on Cervix Uteri

  • In 771 women given metronidazole for the treatment of vaginal trichomoniasis, more cancers developed than had been expected after exclusion of carcinoma of one uterine cervix (observed, 24 cases; expected on the basis of the Connecticut Tumor Registry, 21.7; expected on the basis of the Third National Cancer Survey, 18.4) [8].
  • Relaxin promotes growth and softening of the cervix, thus facilitating rapid delivery of live young [9].
  • INTERVENTION: Women self-collected a vaginal swab for HPV testing in the clinic and were then screened using 4 different tests: Papanicolaou smear, direct visual inspection of the cervix after the application of 5% acetic acid, cervicography, and HPV DNA testing of a clinician-obtained cervical sample [10].
  • Moreover, nucleolin expression is altered in HPV18(+) precancerous and cancerous tissue from the cervix uteri [11].
  • We examined microvessel density and expression of vascular endothelial growth factor in specimens of cervical intraepithelial neoplasia (CIN), a preinvasive lesion of the uterine cervix, to determine whether a connection could be established between these parameters of angiogenesis and the grade of dysplasia (i.e., tissue abnormality) [12].

Chemical compound and disease context of Cervix Uteri

  • CONCLUSION: CIFX improved the response rate and PFS duration in advanced cervix cancer compared with cisplatin alone, but at the cost of greater toxicity and with no improvement in survival [13].
  • CONCLUSION: This study demonstrates that for patients with locally advanced carcinoma of the cervix, the combination of 5-FU and CF with RT offers patients better PFS and overall survival than HU, and with manageable toxicity [14].
  • This study prospectively evaluates the combination of bleomycin to this regimen in women with histologically proven advanced recurrent or persistent squamous cell carcinoma of the cervix [15].
  • Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study [15].
  • After hysterectomy, 156 evaluable patients with stage I (limited to the corpus) or stage II (limited to the corpus and cervix) uterine sarcomas were randomly assigned to adjuvant chemotherapy with Adriamycin (Adria Laboratories, Columbus, Ohio) for six months or to no further treatment [16].

Biological context of Cervix Uteri


Anatomical context of Cervix Uteri

  • Indium-111 labelled monoclonal antibody to placental alkaline phosphatase in in the detection of neoplasms of testis, ovary, and cervix [22].
  • Two proinflammatory cytokines, interleukin 1 alpha (IL-1 alpha) and tumor necrosis factor alpha (TNF-alpha), inhibited proliferation of normal epithelial cells cultured from human cervix [23].
  • Whereas normal cervical epithelium demonstrated diffuse, moderate to intense cytoplasmic staining, many pathological lesions of the cervix displayed reduced or absent Fhit expression [24].
  • In normal tissues, EAG mRNA is almost exclusively expressed in brain, but it is expressed in several somatic cancer cell lines, including HeLa, from cervix [25].
  • Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study [14].

Associations of Cervix Uteri with chemical compounds


Gene context of Cervix Uteri


Analytical, diagnostic and therapeutic context of Cervix Uteri


  1. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Cappellen, D., De Oliveira, C., Ricol, D., de Medina, S., Bourdin, J., Sastre-Garau, X., Chopin, D., Thiery, J.P., Radvanyi, F. Nat. Genet. (1999) [Pubmed]
  2. Rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix. An update. Melnick, S., Cole, P., Anderson, D., Herbst, A. N. Engl. J. Med. (1987) [Pubmed]
  3. Increased incidence of cervical and vaginal dysplasia in 3,980 diethylstilbestrol-exposed young women. Experience of the National Collaborative Diethylstilbestrol Adenosis Project. Robboy, S.J., Noller, K.L., O'Brien, P., Kaufman, R.H., Townsend, D., Barnes, A.B., Gundersen, J., Lawrence, W.D., Bergstrahl, E., McGorray, S. JAMA (1984) [Pubmed]
  4. Cost-effectiveness of combined treatment for endocervical gonorrhea. Considering co-infection with Chlamydia trachomatis. Washington, A.E., Browner, W.S., Korenbrot, C.C. JAMA (1987) [Pubmed]
  5. 13-cis-retinoic acid plus interferon-alpha 2a in locally advanced squamous cell carcinoma of the cervix. Lippman, S.M., Kavanagh, J.J., Paredes-Espinoza, M., Delgadillo-Madrueño, F., Paredes-Casillas, P., Hong, W.K., Massimini, G., Holdener, E.E., Krakoff, I.H. J. Natl. Cancer Inst. (1993) [Pubmed]
  6. Activity of the genital tract and plasma levels of oxytocin and cortisol at the time of mating in the ewe. Garcia-Villar, R., Schams, D., Alvinerie, M., Laurentie, M.P., Toutain, P.L. J. Endocrinol. (1985) [Pubmed]
  7. Vasoactive intestinal polypeptide (VIP) inhibits neurally evoked smooth muscle activity of rat uterine cervix in vitro. Stjernquist, M., Owman, C. Regul. Pept. (1984) [Pubmed]
  8. Lack of evidence for cancer due to use of metronidazole. Beard, C.M., Noller, K.L., O'Fallon, W.M., Kurland, L.T., Dockerty, M.B. N. Engl. J. Med. (1979) [Pubmed]
  9. Relaxin's physiological roles and other diverse actions. Sherwood, O.D. Endocr. Rev. (2004) [Pubmed]
  10. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. Wright, T.C., Denny, L., Kuhn, L., Pollack, A., Lorincz, A. JAMA (2000) [Pubmed]
  11. Nucleolin as activator of human papillomavirus type 18 oncogene transcription in cervical cancer. Grinstein, E., Wernet, P., Snijders, P.J., Rösl, F., Weinert, I., Jia, W., Kraft, R., Schewe, C., Schwabe, M., Hauptmann, S., Dietel, M., Meijer, C.J., Royer, H.D. J. Exp. Med. (2002) [Pubmed]
  12. Correlation of vascular endothelial growth factor expression and microvessel density in cervical intraepithelial neoplasia. Obermair, A., Bancher-Todesca, D., Bilgi, S., Kaider, A., Kohlberger, P., Müllauer-Ertl, S., Leodolter, S., Gitsch, G. J. Natl. Cancer Inst. (1997) [Pubmed]
  13. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. Omura, G.A., Blessing, J.A., Vaccarello, L., Berman, M.L., Clarke-Pearson, D.L., Mutch, D.G., Anderson, B. J. Clin. Oncol. (1997) [Pubmed]
  14. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. Whitney, C.W., Sause, W., Bundy, B.N., Malfetano, J.H., Hannigan, E.V., Fowler, W.C., Clarke-Pearson, D.L., Liao, S.Y. J. Clin. Oncol. (1999) [Pubmed]
  15. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. Bloss, J.D., Blessing, J.A., Behrens, B.C., Mannel, R.S., Rader, J.S., Sood, A.K., Markman, M., Benda, J. J. Clin. Oncol. (2002) [Pubmed]
  16. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. Omura, G.A., Blessing, J.A., Major, F., Lifshitz, S., Ehrlich, C.E., Mangan, C., Beecham, J., Park, R., Silverberg, S. J. Clin. Oncol. (1985) [Pubmed]
  17. Randomised trial of nitric oxide donor versus prostaglandin for cervical ripening before first-trimester termination of pregnancy. Thomson, A.J., Lunan, C.B., Ledingham, M., Howat, R.C., Cameron, I.T., Greer, I.A., Norman, J.E. Lancet (1998) [Pubmed]
  18. High-level expression of the retinoic acid receptor beta gene in normal cells of the uterine cervix is regulated by the retinoic acid receptor alpha and is abnormally down-regulated in cervical carcinoma cells. Geisen, C., Denk, C., Gremm, B., Baust, C., Karger, A., Bollag, W., Schwarz, E. Cancer Res. (1997) [Pubmed]
  19. Keratin subtypes in carcinomas of the uterine cervix: implications for histogenesis and differential diagnosis. Ivanyi, D., Groeneveld, E., Van Doornewaard, G., Mooi, W.J., Hageman, P.C. Cancer Res. (1990) [Pubmed]
  20. Human tumor fluorouracil trapping: clinical correlations of in vivo 19F nuclear magnetic resonance spectroscopy pharmacokinetics. Presant, C.A., Wolf, W., Albright, M.J., Servis, K.L., Ring, R., Atkinson, D., Ong, R.L., Wiseman, C., King, M., Blayney, D. J. Clin. Oncol. (1990) [Pubmed]
  21. Frequent loss of KAI1 expression in squamous and lymphoid neoplasms. An immunohistochemical study of archival tissues. Geradts, J., Maynard, R., Birrer, M.J., Hendricks, D., Abbondanzo, S.L., Fong, K.M., Barrett, J.C., Lombardi, D.P. Am. J. Pathol. (1999) [Pubmed]
  22. Indium-111 labelled monoclonal antibody to placental alkaline phosphatase in in the detection of neoplasms of testis, ovary, and cervix. Epenetos, A.A., Snook, D., Hooker, G., Begent, R., Durbin, H., Oliver, R.T., Bodmer, W.F., Lavender, J.P. Lancet (1985) [Pubmed]
  23. Interleukin 1 alpha and tumor necrosis factor alpha stimulate autocrine amphiregulin expression and proliferation of human papillomavirus-immortalized and carcinoma-derived cervical epithelial cells. Woodworth, C.D., McMullin, E., Iglesias, M., Plowman, G.D. Proc. Natl. Acad. Sci. U.S.A. (1995) [Pubmed]
  24. Abnormal Fhit expression in malignant and premalignant lesions of the cervix. Birrer, M.J., Hendricks, D., Farley, J., Sundborg, M.J., Bonome, T., Walts, M.J., Geradts, J. Cancer Res. (1999) [Pubmed]
  25. Ether a go-go potassium channels as human cervical cancer markers. Farias, L.M., Ocaña, D.B., Díaz, L., Larrea, F., Avila-Chávez, E., Cadena, A., Hinojosa, L.M., Lara, G., Villanueva, L.A., Vargas, C., Hernández-Gallegos, E., Camacho-Arroyo, I., Dueñas-González, A., Pérez-Cárdenas, E., Pardo, L.A., Morales, A., Taja-Chayeb, L., Escamilla, J., Sánchez-Peña, C., Camacho, J. Cancer Res. (2004) [Pubmed]
  26. Cancer and dysplasia of cervix in relation to reduced lymphocytic cortisol metabolism-enhancing effect. Klein, A., Storch, B., Beckerman, A., Meyerson, E., Colev, S., Kaufmann, H., Schachter, A. J. Natl. Cancer Inst. (1984) [Pubmed]
  27. Extra-amniotic prostaglandin E2 and the unfavourable cervix. Shepherd, J., Sims, C., Craft, I. Lancet (1976) [Pubmed]
  28. Oestradiol applied locally to ripen the unfavourable cervix. Gordon, A.J., Calder, A.A. Lancet (1977) [Pubmed]
  29. Response of glassy-cell carcinoma of the cervix to cisplatin, epirubicin, and mitomycin C. Mikami, M., Ezawa, S., Sakaiya, N., Komuro, Y., Tei, C., Fukuchi, T., Mukai, M. Lancet (2000) [Pubmed]
  30. Cervical priming with prostaglandin E1 analogues, misoprostol and gemeprost. el-Refaey, H., Calder, L., Wheatley, D.N., Templeton, A. Lancet (1994) [Pubmed]
  31. Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1. Sales, K.J., Katz, A.A., Howard, B., Soeters, R.P., Millar, R.P., Jabbour, H.N., Soeters, R.P. Cancer Res. (2002) [Pubmed]
  32. Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. Sheu, B.C., Lien, H.C., Ho, H.N., Lin, H.H., Chow, S.N., Huang, S.C., Hsu, S.M. Cancer Res. (2003) [Pubmed]
  33. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Acs, G., Zhang, P.J., McGrath, C.M., Acs, P., McBroom, J., Mohyeldin, A., Liu, S., Lu, H., Verma, A. Am. J. Pathol. (2003) [Pubmed]
  34. p53 gene mutations and MDM2 amplification are uncommon in primary carcinomas of the uterine cervix. Kessis, T.D., Slebos, R.J., Han, S.M., Shah, K., Bosch, X.F., Muñoz, N., Hedrick, L., Cho, K.R. Am. J. Pathol. (1993) [Pubmed]
  35. Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. Hill, S.C., Youde, S.J., Man, S., Teale, G.R., Baxendale, A.J., Hislop, A., Davies, C.C., Luesley, D.M., Blom, A.M., Rickinson, A.B., Young, L.S., Eliopoulos, A.G. J. Immunol. (2005) [Pubmed]
  36. Controlled trial of repeated halothane anaesthetics in patients with carcinoma of the uterine cervix treated with radium. Trowell, J., Peto, R., Smith, A.C. Lancet (1975) [Pubmed]
  37. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. Eifel, P.J., Winter, K., Morris, M., Levenback, C., Grigsby, P.W., Cooper, J., Rotman, M., Gershenson, D., Mutch, D.G. J. Clin. Oncol. (2004) [Pubmed]
  38. Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix. Pignata, S., Silvestro, G., Ferrari, E., Selvaggi, L., Perrone, F., Maffeo, A., Frezza, P., Di Vagno, G., Casella, G., Ricchi, P., Cormio, G., Gallo, C., Iodice, F., Romeo, F., Fiorentino, R., Fortuna, G., Tramontana, S. J. Clin. Oncol. (1999) [Pubmed]
  39. Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: a gynecologic oncology group study. Morris, M., Blessing, J.A., Monk, B.J., McGehee, R., Moore, D.H. J. Clin. Oncol. (2004) [Pubmed]
WikiGenes - Universities